MedTrace Logo

A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer

NCT00585052 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-01-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if the treatment combination of paclitaxel and lovastatin is more effective than the currently available chemotherapy for refractory or relapsed ovarian cancer. This research is being done to improve on currently available chemotherapy for ovarian cancer.

Conditions

Interventions

DRUG

Paclitaxel

Paclitaxel will be given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly

DRUG

Lovastatin

Lovastatin, 80 mg, po, daily will be self-administered by the subject.

Sponsors & Collaborators

  • University of Iowa

    lead OTHER

Principal Investigators

  • Raymond Hohl, MD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2010-02-28
Completion
2013-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00585052 on ClinicalTrials.gov